FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Azacitidine for Injection
Status: Currently in Shortage
»Date first posted: 12/18/2020
»Therapeutic Categories: Oncology

Expand all

Accord Healthcare Inc. (Revised 02/25/2021)

Company Contact Information:
866-941-7875, option 2

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg per vial (NDC 16729-306-10) Limited availability. Estimated shortage duration: TBD Shortage of an active ingredient

Armas Pharmaceuticals Inc (New 12/18/2020)

Company Contact Information:
1-732-637-1971

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg per vial (NDC 72485-201-01) Currently on backorder Additional lots are manufactured. Product will be made available as it is released. Demand increase for the drug

Celgene Corporation (Revised 02/10/2021)

Company Contact Information:
1-888-423-5436

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg single-dose vial in cartons of 1 vial, (NDC 0781-3253-94) Available Distributed by Sandoz, Inc. Contact number 800-525-8747
100 mg single-dose vial in cartons of 1 vial, (NDC 0781-9253-94) Available NOVAPLUS labeling. Distributed by Sandoz, Inc. Contact number 800-525-8747
VIDAZA, , 100 mg single-dose vial in cartons of 1 vial, (NDC 59572-102-01) Limited inventory, on allocation Demand increase for the drug

Dr. Reddy's Laboratories, Inc. (Revised 02/19/2021)

Company Contact Information:
1-866-732-3952

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg per vial, (NDC 43598-305-62) Low inventory Partial shipments on allocation through March Demand increase for the drug

Fresenius Kabi USA, LLC (Revised 02/16/2021)

Company Contact Information:
1-888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg per vial, single dose vial, PF, (NDC 63323-771-39) Backordered. Next release April 2021. Demand increase for the drug

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 02/05/2021)

Company Contact Information:
1-800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg per vial, (NDC 0143-9606-01) This presentation is temporarily on backorder. Additional lots are scheduled for manufacturing and will be available in February 2021. Product will be made available as it is released Demand increase for the drug

Mylan Pharmaceuticals Inc. (Reverified 03/02/2021)

Company Contact Information:
1-800-7966-9526

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg per vial (NDC 67457-254-30) Unavailable Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English